Upper Tract Urothelial Carcinoma Clinical Trials

8 recruiting

Upper Tract Urothelial Carcinoma Trials at a Glance

11 actively recruiting trials for upper tract urothelial carcinoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Shanghai, Houston, and Indianapolis. Lead sponsors running upper tract urothelial carcinoma studies include RenJi Hospital, Tianjin Medical University Second Hospital, and Ferring Pharmaceuticals.

Browse upper tract urothelial carcinoma trials by phase

Treatments under study

About Upper Tract Urothelial Carcinoma Clinical Trials

Looking for clinical trials for Upper Tract Urothelial Carcinoma? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Upper Tract Urothelial Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Upper Tract Urothelial Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA

Upper Tract Urothelial Carcinoma
Henry Ford Health System10 enrolled1 locationNCT06948552
Recruiting
Phase 1

Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+2 more
Beijing Biotech42 enrolled1 locationNCT07492628
Recruiting
Not Applicable

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial

Urothelial CarcinomaBladder CancerUpper Tract Urothelial Carcinoma+1 more
University of Washington128 enrolled1 locationNCT06040762
Recruiting
Phase 1Phase 2

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

Low-grade Upper Tract Urothelial Carcinoma
Ferring Pharmaceuticals20 enrolled7 locationsNCT06668493
Recruiting
Not Applicable

Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical Trial

Lymph Node DissectionUpper Tract Urothelial Carcinoma
Tianjin Medical University Second Hospital150 enrolled1 locationNCT07321210
Recruiting

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

Muscle Invasive Upper Tract Urothelial Carcinoma
RenJi Hospital84 enrolled1 locationNCT05595408
Recruiting
Phase 2

Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC

Upper Tract Urothelial Carcinoma
Samsung Medical Center48 enrolled1 locationNCT07225374
Recruiting
Phase 1

Ambulatory Flexible URS for UTUC Surveillance

Upper Tract Urothelial Carcinoma
Chinese University of Hong Kong10 enrolled2 locationsNCT06848868
Recruiting
Phase 2

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Neoadjuvant TherapyPD-1 InhibitorUpper Tract Urothelial Carcinoma+1 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07126119
Recruiting
Phase 2

A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma

CarcinomaUpper Tract Urothelial CarcinomaUTUC
Jinling Hospital, China30 enrolled1 locationNCT05917158
Recruiting

Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy

Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
RenJi Hospital106 enrolled1 locationNCT06204406